Pollsters have been busy this year tracking public sentiment around the top issues of concern for voters. Recent public polling shows that voters priorities have shifted dramatically over the course of the year. With the election less than two weeks away, what is truly on the top of voter’s minds?
As COVID-19 remains among the top issues for voters, our member companies remain focused on achieving one common goal: finding solutions to diagnose, treat, prevent and ultimately end this global pandemic. For decades, the innovative biopharmaceutical industry has continuously pushed the boundaries of science, investing in new technology, research and treatments that help advance medicine, which has enabled us to quickly ramp up the process to find potential treatments and vaccines for COVID-19. We are also working to expand manufacturing capabilities, increase testing and provide financial support and resources.
Additionally, the biopharmaceutical industry has long been an innovation and economic driver in the United States. In fact, since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone and supporting four million U.S. jobs.
While overall drug costs remain in line with inflation, more and more Americans are facing higher out-of-pocket costs as a result of changes in insurance benefit design. To truly fix the system and address patient affordability challenges, we need long-term solutions like lowering patient cost sharing, reforming the rebate system, and requiring plans to count cost-sharing assistance toward deductibles and out-of-pocket limits rather than excluding it from these calculations.
Ahead of Election Day, and as policymakers consider changes to the health care system, they should have all the facts about where voter priorities truly are. PhRMA will continue advocating to help fixing the health care system so that it works better for patients.